Bivirkningshyppigheden havde ingen relation til dosis (inden for det rekommanderede dosisinterval), køn, alder, race eller behandlingsvarighed.
The incidence of adverse events was not related to dose (in the recommended dose range), gender, age, race, or duration of treatment.